Health Care • Medical/Dental Instruments
$5.06 ▲ +0.23
(+4.76%)
MKT CAP: $329.1M • VOL: 368.1K
52W L $1 52W H $7
TMCI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $212.7M | $209.4M | $187.1M |
| YoY Revenue Growth % | +1.6% | +11.9% | — |
| Gross Profit | $169.8M | $168.3M | — |
| Gross Margin % | 79.8% | 80.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$54.2M | -$55.7M | -$51.4M |
| Operating Margin % | -25.5% | -26.6% | -27.5% |
| Net Income (GAAP) | -$59.0M | -$55.7M | -$50.0M |
| EBITDA (Normalized) | -$43.3M | -$46.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$16.0M | -$37.2M | -$34.6M |
| Capital Expenditures (CapEx) | $13.5M | $11.6M | — |
| Free Cash Flow (FCF) | -$29.5M | -$48.8M | -$34.6M |
| FCF Margin % | -13.9% | -23.3% | -18.5% |
| Return on Invested Capital (ROIC %) | -32.4% | -28.4% | — |
| Cash & Short-Term Equivalents | $10.7M | $11.3M | — |
| Total Debt (Short + Long Term) | $55.6M | $53.3M | — |
| Total Stockholders' Equity | $87.3M | $112.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TMCI.